Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 6/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440613 | 0.99 | PTGES (0.59) | PTGESGAAMAPTEPHX2ATM | |
| SCHEMBL1440322 | 0.91 | PTGES (0.52) | PTGESGAAMAPTEPHX2ATM | |
| SCHEMBL1440337 | 0.85 | PTGES (0.56) | PTGESMAPT | |
| SCHEMBL1439792 | 0.84 | PTGES (0.80) | PTGESEPHX2 | |
| SCHEMBL20702176 | 0.84 | PTGES (0.54) | PTGESMAPT | |
| SCHEMBL1440663 | 0.84 | PTGES (0.54) | PTGESGAAMAPT | |
| SCHEMBL1440225 | 0.83 | PTGES (0.74) | PTGESEPHX2 | |
| SCHEMBL1439931 | 0.83 | PTGES (0.53) | PTGESMAPT | |
| SCHEMBL12811631 | 0.83 | PTGES (0.53) | PTGESGAAMAPTEPHX2ACKR3 | |
| SCHEMBL12811519 | 0.82 | PTGES (0.76) | PTGESEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011023812-A1 | MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS | NOVASAID AB (SE) | 2011-03-03 | — | — | WO | claimed |
| US-20220218670-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | GESYNTA PHARMA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20190038603-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | GESYNTA PHARMA AB (SE) | 2019-02-07 | — | — | US | disclosed |
| WO-2011023812-A1 | MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS | NOVASAID AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023812-A1 | MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS | NOVASAID AB (SE) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218670-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | PTGIS, PTGIR, PTGER1 | PTGES 4/4885GAA 1014/4885MAPT 2141/4885 |
| US-20190038603-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | PTGIS, PTGIR, PTGER1 | PTGES 4/4885GAA 1014/4885MAPT 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.